AC
TYRA icon

AXQ Capital’s Tyra Biosciences TYRA Stock Holding History

AXQ Capital’s Portfolio TYRA Stock Details TYRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-12,350
Closed -$118K – 832
2025
Q2 		$118K Buy
12,350
+2,048
+20% +$19.5K 0.04% 508
2025
Q1 		$95.8K Buy
+10,302
New +$133K 0.04% 443

Other funds holding TYRA

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
APMC
Alta Partners Management Company Jackson, Wyoming $151M AUM 296.21% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
CPX
Canaan Partners XI Menlo Park, California $76.1M AUM 638.59% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

AXQ Capital's TYRA Position: Q3 2025 in Review

AXQ Capital sold out of Tyra Biosciences (TYRA) in Q3 2025, closing a stake of 12,350 shares — an estimated $118K sold.

AXQ Capital first reported a position in TYRA in Q1 2025 and held it in 2 quarters. The position peaked at $118K in Q2 2025. 116 funds tracked by Wall St. Rank hold TYRA as of Q3 2025.

  • AXQ Capital reported no remaining Tyra Biosciences position as of Q3 2025 after selling out during the quarter.
  • AXQ Capital sold 12,350 Tyra Biosciences shares in Q3 2025, an estimated $118K.
  • AXQ Capital first reported a position in Tyra Biosciences in Q1 2025 and held it in 2 quarters.
  • AXQ Capital's Tyra Biosciences position peaked at $118K in Q2 2025.
  • 116 funds tracked by Wall St. Rank held Tyra Biosciences as of Q3 2025.

Based on AXQ Capital's 13F filing for Q3 2025, filed 10 Nov 2025.